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Genome-Wide Analysis of Cutaneous T-Cell
Lymphomas Identifies Three Clinically Relevant
Classes
Elodie Laharanne1,2, Naı¨ma Oumouhou3, Franc¸oise Bonnet4, Martina Carlotti1, Catherine Gentil3,
Edith Chevret1, Thomas Jouary5, Michel Longy4, Be´atrice Vergier1,2, Marie Beylot-Barry1,6 and
Jean-Philippe Merlio1,2
This study was undertaken to identify recurrent genetic alterations of the three main types of cutaneous T-cell
lymphomas (CTCLs): mycosis fungoides (MF), Se´zary syndrome (SS), and cutaneous anaplastic large-cell
lymphoma (CALCL). Using array-based comparative genomic hybridization, the molecular cytogenetic profiles
of 72 samples obtained from 58 patients with CTCL corresponding to 24 transformed MF (T-MF), 16 SS, and 18
CALCLs were determined. T-MF was characterized by gains of 1q25–31, 7p22–11.2, 7q21, 7q31, and 17q12, and
losses of 9p21, 10p11.2, and 10q26. SS exhibited gains of 8q23–24.3 and 17q23–24, as well as losses of 9p21,
10p12–11.2, 10q22–24, 10q25–26, and 17p13–q11.1. Finally, CALCL exhibited 6q27 and 13q34 losses. Such
imbalances were statistically associated with one CTCL subtype. Unsupervised hierarchical clustering defined
three categories of clinical relevance: (1) CALCL apart from epidermotropic-CTCL, (2) an SS-only category, and
(3) a mixed category with T-MF and SS cases, with both primary and secondary SS cases. In rare cases, the
genetic classification did not correspond to the inclusion diagnosis, possibly reflecting the association of two
diseases in the same patient or initial misdiagnosis according to follow-up. Finally, different samples in the same
patient clustered together, showing reproducibility of such a classifier.
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INTRODUCTION
According to the WHO (World Health Organization)/EORTC
(European Organization of Research and Treatment of
Cancer) classification, cutaneous T-cell lymphomas (CTCLs)
represent a heterogeneous group of diseases allocated to
separate entities in the WHO classification of hematopoietic
and lymphoid tumors (Willemze et al., 2005; Swerdlow et al.,
2008). CTCL classification is not supported by genetics and
does not identify patients at risk for progressive disease,
except for rare aggressive CTCL subtypes, such as Se´zary
syndrome (SS), gd-T-cell lymphoma, and aggressive epider-
motropic CD8þ cytotoxic T-cell lymphoma (Willemze et al.,
2005).
Epidermotropic CTCLs (eCTCLs) account for at least 50%
of cutaneous lymphomas and include mycosis fungoides (MF)
and SS (Willemze et al., 2005). Both MF and SS share the
same staging system, present overlapping features, and
may be combined in secondary SS occurring in patients with
MF (Willemze et al., 2005; Olsen et al., 2007). At early
patch/plaque tumor node metastasis (TNM) stage (IA–IIA),
patients with MF have a survival comparable to that of age-
matched healthy individuals. More than two-thirds of patients
with MF will not progress to advanced or late TNM stages
(IIB–IVB). In contrast to MF, SS is a rare form of eCTCL with de
novo advanced or ‘‘late’’ TNM stage (III or IV) and an
aggressive clinical course with a 5-year survival rate of only
24% (Willemze et al., 1997; Willemze et al., 2005).
However, patients with SS may also exhibit strong differences
in disease progression and therapeutic response (Olsen et al.,
2007).
The updated TNM stage is by far the most important
prognostic factor, and the risk of disease progression
correlates with the severity of the initial T classification
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(Kim et al., 2003; Olsen et al., 2007). Detection of the same
T-cell monoclonal rearrangement in the skin and blood may
identify patients at risk of disease progression or treatment
failure (Beylot-Barry et al., 2001; Fraser-Andrews et al.,
2001). Histological large-cell (425%) transformation (LCT)
observed in patients with either MF or SS, hereafter called
transformed MF (T-MF) or transformed type of SS (T-SS),
represents a turnover in eCTCL course associated with tumor
formation, extracutaneous spreading, and a median survival
time of 22 months (Diamandidou et al., 1998; Vergier et al.,
2000). The occurrence of LCT was found to be highly
dependent on TNM stage at diagnosis, suggesting a better
prognosis for de novo LCT than LCT after early-stage MF/SS
(Arulogun et al., 2008).
The oncogenic alterations that sustain aggressive forms of
MF/SS are so far poorly identified, despite numerous studies
using conventional cytogenetics, allelotyping, comparative
genomic hybridization (CGH), or fluorescence in situ
hybridization (Karenko et al., 1997, 1999; Scarisbrick et al.,
2000, 2001; Mao et al., 2003a, c; Fischer et al., 2004;
Prochazkova et al., 2007). Many recurrent chromosomal
imbalances (CIs) or rearrangements have been described in
MF and SS, with relatively poor reproducibility between
series. Losses involving chromosomes 1p, 17p, 10q/10, and
19, and gains of 17q and 18, with minimal common regions
(MCRs) of deletion at 1p31–p36 and 10q26, have been
described as common alterations in MF/SS patients, support-
ing the fact that MF and SS may represent the clinical
spectrum of a common biological entity (Mao et al., 2002,
2003a). Accordingly, NAV3 translocation/deletion at
12q21–q22 has been detected in B50% of early-stage MF
and in up to 85% of late-stage MF/SS (Karenko et al., 2005),
although we have not confirmed such data (Marty et al.,
2008). More recently, deregulated expression of transcription
factors of the activator protein-1 family, JUNB in SS and
JUND in MF, was described following previous reports
of JUNB gain and increased expression in MF, SS, and
cutaneous CD30þ anaplastic large-cell lymphoma (CALCL)
(Mao et al., 2003c, 2004, 2008).
Recently, two major studies, 1 of 20 SS cases (Vermeer
et al., 2008) and 1 of 22 T-MF cases (van Doorn et al., 2009),
were carried out using a 3,500 (3.5 K) bacterial artificial
chromosome (BAC) array at the Leiden University
Medical Centre. The pattern of CI in SS included gains on
chromosomes 17q24 and 8q24 and losses of regions on
17p13 and 10q25 (Vermeer et al., 2008), whereas T-MF
exhibited gains of 7q36 and 7q21–7q33 and losses of 5q13
and 9p21 (van Doorn et al., 2009). These data support the
fact that the two diseases follow a different oncogenomic
pathway (van Doorn et al., 2009). Prognosis impact was
determined in the T-MF subgroup and interestingly
showed that besides 9p21 loss, 8q24 gain, a CI also found
in SS patients, was associated with poor prognosis (van
Doorn et al., 2009). A recent oligonucleotide array-CGH
(a-CGH) study of 41 skin samples of T-MF, which included
10 cases of the previous BAC array study, confirmed
these data for T-MF (Salgado et al., 2009; van Doorn et al.,
2009).
After eCTCL, the second most frequent CTCL subtype is
CALCL, which, with a 96% 5-year survival rate, has a much
more favorable prognosis than does systemic CD30þ CALCL
(Stein et al., 2000; Willemze et al., 2005). CALCL usually
presents as a solitary cutaneous or subcutaneous tumor, less
commonly as multiple tumor nodules (Paulli et al., 1995;
Bekkenk et al., 2000; Willemze et al., 2005). However,
B20% of patients with CALCL may experience harmful
relapsing skin disease, sometimes with extracutaneous
spreading (Paulli et al., 1995; Bekkenk et al., 2000). Some
specific CIs have been identified by CGH (Mao et al.,
2003b, c; Prochazkova et al., 2003). A parallel a-CGH study
recently described different CIs in 11 cases of CALCL and
in 10 cases of cutaneous peripheral T-cell lymphoma not
otherwise specified, a rare CD30-negative disease with a
more aggressive behavior (van Kester et al., 2010). However,
we, along with others, reported rearrangements of the interferon
regulatory factor (IRF4) gene in CD30-positive CTCL patients,
including a subset of CALCL cases (26%) and T-MF cases (18%)
(Feldman et al., 2009; Pham-Ledard et al., 2009). The differential
diagnosis between CALCL and T-MF expressing the CD30
antigen may be problematic in some instances and there is
no immunohistochemical or genetic gold standard criterion
with which to differentiate these CD30-positive IRF4-positive
anaplastic lymphoma kinase-negative diseases (Vergier et al.,
1998; Benner et al., 2009; Pham-Ledard et al., 2009).
To determine the genetic profile of each CTCL subtype, we
performed a large a-CGH analysis of 72 samples obtained
from 58 patients with CTCL, including 24 T-MF, 16 SS, and
18 CALCL cases. Statistical analyses identified the most
relevant CI with diagnostic significance. An unsupervised
genetic classification was found to define three clinically
relevant groups: a first common T-MF and SS subgroup, a
second SS-only group, and a third CALCL group, thus
providing a genetic basis for CTCL classification. The
reproducibility of such an approach was also tested using
different statistical algorithms providing coherent data.
RESULTS
Pattern of copy number alterations in CTCL
Array-CGH analysis was performed in 34 samples obtained
from 24 patients with T-MF, in 16 samples from 16 patients
with SS, and in 22 samples from 18 patients with CALCL.
Clinical data with TNM stage and follow-up are presented in
Supplementary Table S1 online (A: T-MF; B: SS; C: CALCL).
For statistical analyses, a CI was defined if at least three BAC
clones showed an abnormal pattern with a log2 ratio higher
than ±0.25 for gains and losses, respectively (Orsetti et al.,
2004; Orsetti et al., 2006). The karyotype representation of
recurrent CIs is shown in Figure 1. Despite material selection
with a tumor cell content above 50, 11% (8 out of 72) of
samples (5 T-MF, 1 SS, and 2 CALCL samples) showed
minimal imbalances below the above threshold.
Apart from these samples, the average number of CIs was
nearly similar in the three different CTCL subtypes, with a
mean of 11.25 alterations in T-MF samples, 8.2 imbalances in
SS samples, and 9.7 events in CALCL samples. In each CTCL
subtype, losses were more frequent than gains (T-MF: 4.7
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gains, 6.68 losses; SS: 2.67 gains, 4.8 losses; CALCL: 3.09
gains, 7.23 losses). Most CIs corresponded to either gains or
losses according to log2 ratio values, and only one SS case
and two T-MF cases were found to exhibit a high level of
amplification (case 3 at 2p16.1–p15, case 4 at 8q24.21, and
case 30 at 2q33.1–33.3). Interestingly, CIs of CALCL were
mainly observed in centromere and telomere chromosomal
regions, and corresponded for the most part to deletions,
suggesting the presence of imbalanced chromosomal
rearrangements.
MCRs of alterations
To identify biologically significant patterns in T-MF, SS, and
CALCL separately, we performed a MCR search using the
VAMP software (Curie Institute, Paris, France) and identified
MCR in at least 30% of cases (http://bioinfo-out.curie.fr/
CAPweb/). The most recurrent CIs were gains of 1q, 7, 8q,
and 17q, and losses of 1p, 6q, 8p23, 9p21, 10, 13q, and 17p.
The MCRs of these CIs are described for each CTCL subtype
in Table 1. T-MF tumors were characterized by a gain of
chromosome 7 and a loss of 9p21 locus, whereas SS cases
were characterized by 8q and 17q gains, and 10q and 17p
deletions. Interestingly, CALCL samples exhibited a different
pattern with losses at 6q and 13q. Some candidate genes
located within the MCR, with possible relevant functions in
cancer or T-cell signaling, are listed in Table 1.
Ploidy analysis
Both T-MF and T-SS may present tetraploid cells (So et al.,
2000; Prochazkova et al., 2005). As a-CGH only detects CI
after normalization of DNA input, aneuploidy would not be
detected and could modify the ratio of an imbalanced allele
versus normal alleles (Andrieux, 2008). We therefore
compared the a-CGH profile of polyploid and diploid cases
of the same CTCL subtype. Ploidy analysis results are
summarized in Supplementary Table S2 online. Out of the
54 samples available for such an analysis, only 9 T-MF (cases
3, 4, 5, 8, 10, 11, 17, 19, and 23) and 3 SS (cases 30, 37, and
38) cases exhibited a triploid or a tetraploid pattern.
Interestingly, one SS polyploid case and three T-MF cases
showed minimal CIs. In the eight other polyploid cases, CIs
similar to those detected in diploid cases were observed.
Surprisingly, all tested CALCL cases (n¼ 10) presented a
diploid pattern despite their large anaplastic morphology.
Oligonucleotide a-CGH analysis
To evaluate whether BAC array analyses would reliably
detect small alterations (Salgado et al., 2009), we analyzed in
parallel 14 samples from T-MF (n¼ 7) and SS (n¼7) by an
oligonucleotide a-CGH (2 105K, Agilent Technologies,
Massy, France). The two methods do not have the same
algorithm, making it difficult to compare the overall number
of break points detected by each technique, as this relies on
criteria used for threshold determination. We therefore
decided to focus on the recurrent CIs and to compare
the number of MCRs detected by each a-CGH method.
In 14 samples, 57 MCRs were detected by BAC a-CGH
and 62 MCRs were detected by oligonucleotide a-CGH.
For each sample and MCR, both methods produced the
same results, except for the 9p21 deletion targeting
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Figure 1. Graphical karyotyping representation of BAC-array profiles using VAMP software showing recurrent chromosomal abnormalities for each subtype
of CTCL lymphoma. Gains are represented in red, losses in green. BAC, bacterial artificial chromosome; CALCL, cutaneous CD30þ anaplastic large-cell
lymphoma; SS, Se´zary syndrome; T-MF, transformed mycosis fungoides.
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MTAP/CDKN2A/CDKN2B genes. This MCR was found to
be very restricted in size at 9p21 and was detected in only
4 cases (2 T-MF and 2 SS) by BAC a-CGH, whereas
oligonucleotide a-CGH detected 9p21 loss in 9 out of 14
cases (5 T-MF and 4 SS).
Statistical relevance of chromosomal alterations
To determine the association of a recurrent CI with a specific
CTCL subtype, we performed statistical analyses (w2 test and
Fisher’s exact test) by comparing a-CGH results with the
inclusion diagnosis. These CIs are summarized in Table 2 with
colored boxes. Gains of 8q and losses of 10q, or 17p arms,
were found to be significantly more frequent in SS than in other
CTCL subtypes. Gains of 7p and/or 7q and 9p loss were more
frequent in T-MF, and CALCL cases were found to display 6q
or 7q losses more frequently. These data suggest that each
CTCL subtype could be characterized by an a-CGH profile,
i.e., an association of certain CIs, but that a single CI could not
be considered as pathognomonic for a CTCL subtype.
Unsupervised classification
To determine the clinical relevance of our analysis, we
performed unsupervised classification of CTCL cases accord-
ing to their a-CGH profile independently from other
parameters. To avoid statistical bias or any other artifact,
we first included only one sample per patient corresponding
to the first available skin biopsy for T-MF and CALCL cases, or
to the first blood sample for SS cases, except for case 5 as
justified below. Several clustering algorithms were applied,
including hierarchical ascending classification (HAC), the
K-means method, and the weighted clustering of called array-
CGH data (WECCA) (Van Wieringen et al., 2008), without
delimiting the threshold limit for CI detection.
Both HAC and K-means clustering of log2 ratio values
were applied to 59 samples obtained from 58 patients and
provided three classes, as shown for HAC (Figure 2a and
Table 3). Class 1 corresponded to a mixed subgroup of T-MF
and SS cases with three T-SS cases (cases 25, 32, and 40),
three SS cases secondary to T-MF (cases 5, 27, and 30), and
Table 1. Minimal common regions identified by VAMP software in at least 30% of each CTCL subtype
Diagnosis Recurrent regions Start Size Candidate genes % Cases
T-MF cases 1q25–q31 gain 182,998,482 10.3Mb RGS1, RGS2 35
7p22–p11.2 gain 2,832,882 52Mb RAC1, OCM 50
7q21 gain 79,412,841 8.6Mb HGF 60
7q31gain 109,973,020 11Mb DOCK4, MET, ING3 50
9p21 loss 22,338,753 860Kb MTAP, CDKN2A, CDKN2B, DMRTA1 30
9q21–q22 loss 86,137,999 5Mb CCRK 35
10p11.2 loss 30,483,820 2.9Mb MAP3K8, ZEB1, ITGB1 30
10q26 loss 120,625,189 14Mb MGMT 40
13q34 loss 109,110,603 4Mb TFDP1 40
16q21–22 loss 63,724,579 2.5Mb CMTM1, CKLF, E2F4, CBFBy 30
16q23–24 loss 81,378,617 7Mb BCAR1, WWOX, CDH13y 35
17q12 gain 31,808,411 2.2Mb PPIP4K2B, MMP28, GRB7, ERBB2y 30
SS cases 8q23–24.3 gain 116,334,846 29.2Mb MYC, NSMCE2, LYNX1 41
10p12–p11.2 loss 26,994,029 6.4Mb RAB18, MAP3K8, ZEB1, ITGB1 41
10p11.2 loss 33,372,747 2 Mb NRP1 41
10q22–24 loss 79,183,602 26 Mb PTEN, FAS, SUFU, NKKB2 47
10q25–26 loss 113,660,893 21.6Mb FGFR2, CASP7, DMBT1 41
11q22–11q23 loss 107,974,233 6.3Mb DDX10 30
17p13–q11.1 loss 489,119 21.8Mb TP53, MAP2K3y 47
17q23–24 gain 57,299,410 3.8Mb ICAM2, MAP3K3 35
CALCL cases 1p36.3 loss 1,189,272 2.4Mb TNFRSF14 30
6q27 loss 170,457,093 232Kb 40
7p11.1–7q11.2 loss 57,806,220 4.2Mb 45
8p23 loss 2,194 1.4Mb 45
13q34 loss 110,616,984 3.4Mb ARHGEF7, TFDP1 45
16p11.2–16p11.1 loss 32,775,011 2.1Mb TP53TG3 45
20p11.1–20q11.2 loss 26,128,609 3.5Mb REM1 30
Abbreviations: CALCL, cutaneous anaplastic large cell lymphoma; CTCL, cutaneous T-cell lymphoma; SS, Se´zary syndrome; T-MF, transformed mycosis fungoides.
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four IVA1 SS cases (cases 29, 34, 35, and 36). In this class 1, the
T-MF skin sample of patient 5 (5S) clustered together with the
SS blood sample (5B), and both samples were included in this
first analysis, as both diseases seemed to develop in parallel
with each specific cytogenetic alteration (Prochazkova et al.,
2005). Class 2 determined an ‘‘SS-only’’ subgroup with most
cases of IVA2 stage or patients (cases 26, 28, and 38) who,
apart from case 38, died in o25 months, as well as cases of
SS preceded by MF (31 and 33) or cases still alive but with
partial response to treatments (cases 37, 38, and 39).
Interestingly, all cases from class 2 exhibited an 8q gain but
such a gain was also found in three SS cases from class 1.
Finally, a third class consisted of all CALCL cases, as
expected from CI analysis. Interestingly, only one case
included as CD30-positive T-MF (case 24) clustered in class
3 with CALCL, as discussed below. As no threshold limit was
used, cases that seem to have minimal imbalances below
threshold by VAMP analysis clustered in the appropriate
category as indicated in bold type in Table 3. Indeed, the five
T-MF patients (cases 8, 19, 21 22, and 23) and the single SS
patient (case 38) clustered in class 1 and 2, respectively,
whereas the two CALCL patients (cases 42 and 48) were
found in class 3 (Table 3).
Another algorithm developed recently for a-CGH cluster-
ing was also evaluated (Van Wieringen et al., 2008). Using
this algorithm, ‘‘called’’ a-CGH data are mapped onto an
ordinal scale, allowing for the weighting of specific clones or
chromosomal regions, as well as the exclusion of ‘‘dull’’ regions
with few aberrations. However, the algorithm was used in a
similar manner to HAC or K-means without data filtering. Thus,
using WECCA, clustering into three categories is possible with
a good general reproducibility with other methods. As seen in
Figure 2b, class 1 was composed of T-MF and SS cases, with
two CALCL cases displaying numerous CIs. Class 2 comprised
T-MF cases, all displaying a gain of chromosome 7 or 7q. Class
3 was composed of most CALCL cases with three T-MF or SS
cases that seemed to cluster separately in a subclass, as seen in
the dendrogram of Figure 2b.
Table 2. Frequency of chromosomal imbalances according to the
inclusion diagnosis and statistical association in colored boxes (red for
gains, green for losses) with P-value of v2 test (or Fisher’s exact test)
CALCL T-MF SS All samples P-values
1q gain, n (%) 4 (22%) 0.0389 
6q loss, n (%) 0.0200 
7p gain, n (%) 2 (11%) 0.0177 
7q gain, n (%) 5 (28%) 0.0136 
7q loss, n (%) 0.0130 
8q gain, n (%) 0.0020 
9p loss, n (%) 13 (68%) 0.0015 
10q loss, n (%) 2 (11%)
2 (11%)
8 (42%) 
17p loss, n (%) 
6 (32%) 0 (0%) 10 (19%) 
9 (50%) 2 (11%) 3 (18%) 14 (26%) 
9 (47%) 2 (12%) 13 (24%) 
11 (58%) 2 (12%) 18 (33%) 
6 (33%) 2 (11%) 0 (0%) 8 (15%) 
1 (6%) 4 (21%) 10 (59%) 15 (28%) 
8 (47%) 23 (43%) 
8 (47%) 18 (33%) 0.0448 
3 (17%) 3 (17%) 9 (53%) 15 (28%) 0.0331 
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Cluster dendrogram
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Figure 2. Dendrograms obtained after unsupervised classification using only one sample per patient except for case 5. (a) Dendrogram obtained by
hierarchical ascending classification using Ward’s method of linkage, and correlation distance as a metric. (b) Dendrogram obtained by weighted clustering of
called array-CGH data (WECCA) software using total linkage and agreement similarity (Van Wieringen et al., 2008).
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Sequential samples of the same patients were included in
HAC or K-means clustering of 72 samples introducing a
statistical bias, as all patients did not have the same number
of samples. Despite this limitation, we observed that different
samples from the same patient clustered together in the
relevant genetic class (data not shown).
Prognostic impact of CIs
In our retrospective study, clinical data are collected in a
single institution in which all patients are prospectively
recorded in a standardized follow-up cohort and treated after
a multidisciplinary review of each case. Survival curves were
established according to the Kaplan–Meier method and the
log-rank test to seek correlation between survival and CI.
Very few patients were lost to follow-up and censored. To
determine which genetic imbalance may support prognostic
difference between the three CTCL subtypes, we first
analyzed all patients together. Only an 8q gain and a 9p21
deletion were found to be significant predictive markers for
shorter survival (log-rank test, P¼ 0.006 and P¼0.0019,
respectively). Such a CI was only observed in patients
with either SS or T-MF. As pooling patients with different
diseases may be a flaw, we analyzed prognosis in the three
separate groups: T-MF, SS, and CALCL. As shown in Figure 3,
Table 3. Genetic classes obtained after unsupervised classification
(HAC)
Class 1 Class 2  Class 3  
Case Diagnosis Case Diagnosis Case Diagnosis 
Case1 T-MF Case26 SS Case24 T-MF CD30+ 
Case2 T-MF Case28 SS Case41 CALCL
Case3 T-MF Case31 SS (sec. to MF) Case42 CALCL 
Case4 T-MF Case33 SS (sec. to MF) Case43 CALCL
Case5Blood SS Case37 SS Case44 CALCL
Case5Skin T-MF Case38 SS Case45 CALCL
Case6 T-MF Case39 SS Case46 CALCL
Case7 T-MF Case47 CALCL
Case8 T-MF Case48 CALCL 
Case9 T-MF Case49 CALCL
Case10 T-MF Case50 CALCL
Case11 T-MF Case51 CALCL
Case12 T-MF Case52 CALCL
Case13 T-MF Case53 CALCL
Case14 T-MF Case54 CALCL
Case15 T-MF Case55 CALCL
Case16 T-MF Case56 CALCL
Case17 T-MF Case57 CALCL
Case18 T-MF Case58 CALCL
Case19 T-MF 
Case20 T-MF 
Case21 T-MF 
Case22 T-MF 
Case23 T-MF 
Case25 T-SS
Case27 SS (sec. to TMF)
Case29 SS
Case30 T-SS (sec. to TMF)
Case32 T-SS Color legend: 
Case34 SS CALCL
Case35 SS T-MF 
Case36 SS SS
Case40 T-SS Minimal imbalances 
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no alteration reached the significance level that may rely on
the small size of each subgroup. In T-MF, 8q gain was
found at P¼0.09 and 9p21 deletion at P¼0.06. In SS, 9p21
loss, 17p loss, and 17q gain were also found at values just
above the threshold (P¼ 0.09, P¼0.09, and P¼0.08,
respectively).
T-MF patients SS patients
SS patients SS patients
T-MF patients
No 8q gain
8q gain
No 9p21 loss
P-value=0.09
P-value=0.09 P-value=0.08
P-value=0.06
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9p21 loss
No 17q gain
17q gain
No 17q loss
17p loss
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Figure 3. Survival curves, obtained using the Kaplan–Meier method, in epidermotropic cutaneous T-cell lymphoma subtypes (transformed mycosis fungoides
(T-MF) and Se´zary syndrome (SS) patients) showing no correlation between overall survival and the chromosomal imbalances tested. For all graphical
representations, P-values are given according to the log-rank test.
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The gain and loss analysis of DNA (GLAD) algorithm of
the VAMP software (automatic detection of break points)
(Hupe et al., 2004; Rouveirol et al., 2006) enabled us to
determine the number of chromosomal breaks. This parameter,
which may reflect genomic instability, was not found to be
correlated with either the CTCL subtype (Kruskall–Wallis test,
P¼ 0.08) or survival (Cox model, P¼0.7) by statistical analysis
(data not shown).
DISCUSSION
Using a-CGH methodology, we analyzed the molecular
cytogenetic profiles of a large series of 72 samples obtained
from 58 patients with CTCL. This study allowed us to
highlight specific CIs significantly associated with a CTCL
subtype, which in turn could be used for diagnostic purpose,
especially in patients with borderline disease. In particular,
T-MF displayed 1q, 7p, or 7q gains, and 9p21 loss. SS cases
usually exhibited 8q24.3 and/or 17q gains associated with
10q and/or 17p losses. Moreover, CALCL appeared as a
distinct disease with fewer CIs, such as 6q27, 8p23, and 13q
losses, or 7q21–31 gain. Our study also allowed the first
hierarchical clustering of CTCL into three genetic subgroups
with clinical relevance.
Specific CIs have been recently reported in separate a-
CGH studies of T-MF, SS, and CALCL, and most of them
appeared after the submission of our data (Vermeer et al.,
2008; Caprini et al., 2009; Salgado et al., 2009; van Doorn
et al., 2009; van Kester et al., 2010). As shown in
Supplementary Table S3 online, a major finding was that
CIs were independently detected at identical loci with nearly
identical MCR, and also at the same prevalence for each
CTCL subset, although we did not use the same a-CGH
platform. Such reproducibility was not achieved previously,
especially by conventional CGH studies of CTCL (Mao et al.,
2003a; Fischer et al., 2004; Prochazkova et al., 2007). Such
concordance between different a-CGH platforms has been
described using a single HL 60 cell line, also showing that
BAC arrays produce less versatile results than do oligonu-
cleotide arrays (Hester et al., 2009), but is relatively original
when using different patient samples. An oligonucleotide a-CGH
study of 41 T-MF samples recently confirmed the genetic
profile of T-MF by including 10 cases already analyzed in a
previous BAC array study (Salgado et al., 2009; van Doorn
et al., 2009). With such a comparison, Salgado et al. (2009)
found that many small alterations, notably losses, may escape
detection by BAC a-CGH. Similarly, in our comparative study
of 14 cases, 9p21 loss was found to escape detection by BAC
array in five cases. However, the rate of detection of each
recurrent CI by BAC a-CGH was found to be equivalent to or
even greater than that reported in the oligonucleotide a-CGH
study by Salgado et al. (2009).
We also observed common CIs between T-MF and SS
cases, such as 9p21 and 10q losses, as reported in T-MF
(Salgado et al., 2009; van Doorn et al., 2009) but not in SS
(Vermeer et al., 2008). Both deletions were indeed reported
in 28 SS cases (32 and 68%, respectively) (Caprini et al.,
2009). Single-nucleotide polymorphism and a-CGH also
showed complex profile chromosome 10 deletions with
either a combination of losses and gains or the concurrent
loss of two regions within 10p12.1–q22.1 and
10q22.3–q26.3, also identified in our study (Caprini et al.,
2009). Whereas 10q deletion in eCTCL, mainly SS, may
encompass PTEN, a well-known tumor suppressor gene
(Scarisbrick et al., 2000), the MCR was not confirmed by
others (Wain et al., 2005). A specific investigation of the
remaining PTEN allele in our cases with a 10q deletion did
not show a PTEN mutation, indicating that PTEN is not the
target of 10q losses (our unpublished data). The NAV3
deletion identified in both MF and SS (Karenko et al., 2005)
was not observed in our cases (Marty et al., 2008). However,
12q21 loss involving the NAV3 gene was reported in 30% of
SS cases (Vermeer et al., 2008), but in only one T-MF case
(Salgado et al., 2009). Apart from three T-MF cases with
nonrecurrent amplification, one of the c-MYC loci (Prochaz-
kova et al., 2007), gains did not correspond to a high level of
amplification, previously described for JUNB in SS (Mao et al.,
2003c). Our data are at variance with another report showing
a subgroup of T-MF with genomic instability, a high level of
amplification at some loci, and a worse prognosis (Salgado
et al., 2009). Tumor sampling at various disease time courses
may explain such a difference. In our experience, most
CTCLs do not exhibit the highly unstable genetic profile
observed in solid tumors, as also observed in SS cases (Blaveri
et al., 2005; Caprini et al., 2009). Hypotetraploidy was also
found as a frequent but not a constant feature of T-MF
(37.5%) or SS (18%), which underscores our previous
findings (Prochazkova et al., 2005; Prochazkova et al.,
2007). No specific CI was found associated with hypote-
traploidy that would suggest that polyploidy and CI may
be independent events. Polyploidy may also lower the
detection of recurrent CIs, as some cases (four out of eight)
with minimal imbalances were indeed polyploid.
Our series is also original in clustering CTCL samples in an
unsupervised analysis. HAC or K-means methods identified
three genetic classes of CTCL in agreement with clinical,
histological, and follow-up data. Our series also defined two
classes of SS, one clustering with T-MF cases and one SS-only
subgroup. Although T-MF and SS have been considered as
two separate oncogenetic entities (Vermeer et al., 2008; van
Doorn et al., 2009), our study would indicate that a subset of
SS and T-MF shares the same genetic profile. This was not
found to correlate with the primary, secondary, or T-SS.
Conversely, CALCL clustered in a distinct subgroup in which
only a single borderline T-MF case was observed. WECCA
was also found to define a common T-MF and SS group, a
T-MF-only group, and a group composed of most CALCL
cases, although some cases were not found in the relevant
clinical category. Indeed, different algorithms were found to
provide nearly identical results for clustering (Blaveri et al.,
2005; Shah et al., 2009).
Our pilot study of a-CGH data by HAC or K-means proved
to be of clinical relevance in several instances. First, cases
with a minimal number of CIs, such as T-MF/SS or CALCL
cases, were blindly classified into the corresponding inclu-
sion category. Some rare cases had original clustering. In case
5, the patient had a history of MF, then developed a typical SS
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with erythroderma and a high blood-cell burden (B2 stage),
and presented T-MF skin tumors with tetraploid cells, as
reported (Prochazkova et al., 2005). Both skin T-MF and
blood SS samples clustered together in class 1. One T-MF
case clustered in the CALCL-specific class (case 24); the
tumor was composed of sheets of CD30þ large cells (at least
50%) occurring in a patient with a history of MF. This case
was also found to display an IRF4 rearrangement, a feature
defining a subset of CD30þ CTCLs (Pham-Ledard et al.,
2009). The good prognosis of case 24 would indicate that the
lesion was a CALCL rather than a T-MF.
Another goal was to identify genetic risk factors for disease
progression. Such a goal is difficult to achieve in retrospective
series and is subject to many statistical biases, especially
when comparing survival curves for a limited number of
patients at advanced stage with censored data. Although
some factors were found at borderline statistical value, such
as 9p21 loss in T-MF and SS, and 8q gain, 17p loss, and 17q
gain in SS, we have not found a clear-cut prognostic impact
of a single specific CI reported by others (Vermeer et al.,
2008; Salgado et al., 2009; van Doorn et al., 2009). A recent
report of 28 SS cases did not individualize significant CI but
found that the association of more than three recurrent CIs
was of prognostic relevance (Caprini et al., 2009). Indeed,
clustering by giving weight to specific chromosomal regions,
as with WECCA or other algorithms, would help to
individualize prognostic groups by compiling data from
different platforms. Such algorithms have been mainly
applied to BAC array data with a uniform distribution of
probes across the genome (Van Wieringen et al., 2008; Shah
et al., 2009; Takeuchi et al., 2009).
The definition of MCR also provides insights into identify-
ing genes that may act as oncogenes or tumor suppressor
genes in CTCL. The correlation of CIs with transcriptome
profiling has been performed in T-MF and SS, and several lists
of potential candidate genes have been proposed (Vermeer
et al., 2008; Caprini et al., 2009; Salgado et al., 2009; van
Doorn et al., 2009). Gains at 8q22–24 are accompanied by an
increased expression of c-MYC, increased c-MYC/MAX
heterodimers, and defects in the c-MYC-induced apoptosis
pathway, possibly by deletion or mutations of downstream
genes, such as TP53 or CDKN2A. These observations suggest
a pivotal role for C-MYC proliferative effects in SS pathogen-
esis (Vermeer et al., 2008). However, 8q24.3 also contains at
least 27 other relevant genes with gain and an increased
expression in T-MF (van Doorn et al., 2009). Apart from this
report, several studies combining a-CGH data and expression
profiles have provided extensive lists of candidate genes but
without functional validation (Caprini et al., 2009; Salgado
et al., 2009; van Doorn et al., 2009; van Kester et al., 2010).
Such data have also to be confirmed in view of the poor
reproducibility of microarray profiling techniques (Marshall,
2004; Sherlock, 2005). Interestingly, CALCL did not bear
gains at 6p25.3, a region containing the IRF4/MUM1
gene, which is highly expressed at the protein level in
CALCL and CD30þ CTCL (Wasco et al., 2008; Benner et al.,
2009). Balanced rearrangements of the IRF4/MUM1 gene
have been recently reported in CALCL and T-MF cases
(Feldman et al., 2009; Pham-Ledard et al., 2009). This is also
a reminder that a-CGH has restrictions for identifying genes
involved in CTCL oncogenesis, detecting only copy number
changes.
A limitation of this study is the focus on patients with
advanced-stage eCTCL and samples with at least 50% of
tumor cells. The study of early-stage MF would identify
genetic alterations that predict initial aggressiveness; how-
ever, tumor cells at such a stage represent no more than 20%
of skin cells (Willemze et al., 2005). A single a-CGH study of
16 early-stage MF cases identified highly recurrent losses of
chromosome 19 (56%), 12q24.31 (44%), 7p22.1–22.3 (19%),
and 7q11.1–11.23 (19%), and gains of 21q22.12 (19%)
(Carbone et al., 2008). Such CIs were not detected in our
T-MF patients nor in two other series (Salgado et al., 2009;
van Doorn et al., 2009). Alternatively, gains at 8q22.3–23.1
and losses at 16q22.3–23.1 were found at early-stage MF (25
and 19%, respectively) (Carbone et al., 2008), and were also
detected in our T-MF cases and in those of van Doorn et al.
(2009) (21 and 30–35%, respectively).
More generally, our study of the three major CTCL
subtypes clearly demonstrates that genetic clustering will
provide new insights for patient diagnosis, together with
clinical and histological criteria. a-CGH provides robust data
that should be included in prospective multicenter therapeu-
tic trials, which in turn will help to identify the most relevant
CIs in multivariate analyses. However, the search for primary
or driver genetic mutations in CTCL, especially in MF, will
require the use of next-generation or deep-sequencing
techniques with high sensitivity (Shendure and Ji, 2008), to
detect genetic mutations and CI in samples with early disease
and a low tumor cell content.
MATERIALS AND METHODS
Selection of patients
We selected 58 patients with primary CTCL according to the WHO-
EORTC criteria (Willemze et al., 2005)—24 T-MF, 16 SS (including 3
SS preceded by MF or T-MF and 4 T-SS), and 18 CALCL—on the
basis of the presence of available fresh-frozen material and informed
consent according to French bioethical law. The study was approved
by the medical ethics committee of the University Hospital of
Bordeaux and conducted according to the Declaration of Helsinki
Principles. From the 24 patients with T-MF, 34 samples were
analyzed either from the skin (n¼ 29), blood (n¼ 3), node (n¼ 1),
or spleen (n¼ 1). For the 16 patients with SS, only blood samples
were studied in patients at B2 stage after lymphocyte separation
gradient. T-SS was observed in patients with SS in which a skin
tumor with LCT developed, together with accelerated leukemic
spreading. For the 18 patients with CALCL, 22 samples were
obtained from the skin (n¼ 20) or lymph node (n¼ 2). CALCLs
were characterized by the expression of CD30þ in 475% of
cells. No lymphomatoid papulosis lesion was included or associ-
ated in patients with CALCL. CD30-positive T-MF were defined
as described previously (Pham-Ledard et al., 2009). Both eCTCL
and non-eCTCL updated criteria were used to assess TNM stages
(Kim et al., 2007; Olsen et al., 2007). These clinical data are
summarized in Supplementary Table S1 online (A, B, C). All samples
contained 450% of tumor cells.
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DNA extraction
High-molecular-weight DNA was extracted from fresh or fresh-
frozen skin biopsy samples by proteinase K digestion and phenol/
chloroform extraction. For uncultured peripheral blood lympho-
cytes, a salt-extraction method was used (Roylance, 2001).
Array-based CGH and data analysis
Array-CGH was performed on BAC microarray consisting of 3,113
BAC clones (called 3-K arrays in latter parts) (Integrachip, Integra-
Gen, Evry, France) or 5,600 BAC clones (called 5-K arrays in latter
parts) (version7: V7, IntegraGen) that covered the human genome at
a 0.5–1Mb resolution. All T-MF samples (n¼ 32) and some SS
patient samples (n¼ 10) were analyzed on 3-K BAC-arrays, whereas
the rest of the SS samples (n¼ 6) and all CALCL (n¼ 24) samples
were performed on a 5-K array. BAC clones were spotted in
quadruplicate. DNA labeling and hybridization methods were
performed as previously described (Orsetti et al., 2004, 2006).
Data were analyzed using the Curie Institute VAMP tool through
the CAPweb bioinformatics platform (http://bioinfo-out.curie.fr/
CAPweb/). Analyses were retained if 490% of BAC clones
presented a good signal-to-noise ratio (of at least 3). A CI was taken
into account if at least three BAC clones showed an abnormal
pattern with a log2 ratio higher than ±0.25 for gains and losses,
respectively (Blaveri et al., 2005; Orsetti et al., 2006). Regions with a
log2 ratio between þ 0.25 and 0.25 were not considered to display
CI, but the value of such a ratio was taken into account in
unsupervised clustering.
To evaluate BAC-array data, 14 DNA samples were also analyzed on
Human Genome Microarray 2 105K (Agilent Technologies, Massy,
France) with a 21.7Kb overall median probe spacing. Hybridization and
scanning were performed according to the manufacturer’s protocol.
Arrays were scanned on G2565BA (Agilent Technologies) and analyzed
using CGH analytics 3.5 software (Agilent Technologies).
Fluorescence in situ hybridization analysis
A total of 29 T-MF samples, 16 SS samples, and 10 CALCL samples
were available for fluorescence in situ hybridization analysis on
frozen imprints, blood samples after short culture, or isolated nuclei
from formalin-fixed paraffin-embedded tissues. A multicolor probe
(Vysis LSI D5S23/D5S721, CEP9, CEP 15 Multi-Color Probe, Vysis,
Rungis, France) was used for ploidy analysis. The same cases were
also investigated for CDKN2A status using Vysis LSI p16 (9p21)
Spectrum Orange/CEP 9 Spectrum Green Probe and for NAV3 status,
as reported earlier (Marty et al., 2008). A total of 100 tumor cells
or nuclei were scored per slide by two independent readers, using
a fluorescent microscope (Zeiss, Jena, Germany) equipped with
appropriate band pass filters. Images were captured using a high-
resolution camera (JAI M300, Germany) and treated with ISIS
software (MetaSystems, Altlussheim, Germany). Tumor samples
were considered triploid or tetraploid if420% of the cells presented
42 signals for each probe.
VAMP analysis
To find MCRs of CI with 30% incidence and to avoid statistical
biases, we excluded samples with minimal imbalances and sequen-
tial samples from the same patient, for example, node or visceral
involvement or second skin biopsies. MCRs were determined by
VAMP software (La Rosa et al., 2006; Hupe et al., 2007).
Statistical analyses
SAS (9.1 version, SAS, Cary, NC) and R software (R Development
Core Team, 2.8.0 version þ R package: ‘‘Survival’’, Auckland, CA)
were used to perform statistical analyses.
Only one sample per patient was conserved, visceral involve-
ment or node samples were discarded. For only one patient (case 5),
we decided to retain one skin and one blood sample, as the disease
evolved with time from MF to SS, then to T-MF with different
cytogenetic clones (Prochazkova et al., 2005). Therefore, analysis
was performed on 59 samples obtained from 58 patients to establish
an independent genetic classification that was thereafter compared
with the inclusion diagnosis. Several clustering algorithms were
applied, including HAC, K-means method, and WECCA (Van
Wieringen et al., 2008). Clustering was performed on BAC-array
probe data corresponding to common clones in the two probe sets
(n¼ 1,914 clones) without delimiting a threshold limit for CI
detection using either log2 ratio from a-CGH analysis for HAC or
K-means. This clustering was carried out for patients using Ward’s
method of linkage and correlation distance as a metric. Another
algorithm developed for a-CGH clustering was also evaluated (Van
Wieringen et al., 2008). In this algorithm, ‘‘called’’ a-CGH data (i.e.,
each location is classified as a loss, a gain, or neutral/no change) are
mapped onto an ordinal scale to provide improved clustering of
continuous data. In WECCA analysis, we used total linkage and
agreement similarity. The algorithm was used in a similar manner to
HAC or K-means without giving weight to specific CI. Statistical
methods included analysis of w2 test and Fisher’s exact test. The
w2 test was used to determine the existence of an association
between two categorical variables, in our case, between CI and the
CTCL subtype. Fisher’s exact test was used instead of w2 test for small
sample sizes. Group comparisons were performed using the
Kruskal–Wallis test. The effect of continuous variable on survival
was achieved using the Cox model.
Survival probabilities were estimated using the Kaplan–Meier
method. The log-rank test was used to compare survival
curves. For all analyses, a P-valuep0.05 was considered statistically
significant.
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